First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers
Saito, Kaku, Nagashima, Hirotaka, Noguchi, Kazuharu, Yoshisue, Kunihiro, Yokogawa, Tatsushi, Matsushima, Eiji, Tahara, Takeshi, Takagi, ShigeruVolume:
73
Language:
english
Journal:
Cancer Chemotherapy and Pharmacology
DOI:
10.1007/s00280-014-2383-2
Date:
March, 2014
File:
PDF, 447 KB
english, 2014